In vitro and in vivo correlation of clotting protease activity: effect of heparin.
The thrombogenicity of three highly purified proteases (thrombin, activated Factor X, and activated Factor IX) was determined quantitatively in an animal model. The minimal amounts required to produce a standard score 4 thrombus were 1.1 nmol for thrombin, 0.12 nmol for activated Factor X, and 0.018 nmol for activated Factor IX. After the administration of heparin at 5, 10, and 20 units/kg in rabbits, the thrombogenicity of each of these proteases decreased progressively. The heparin-induced inhibition of thrombosis decreased in the order, activated Factor IX > activated Factor X > thrombin at each heparin concentration. These differences were statistically significant. These in vivo data provide support for the following hypotheses originally developed from in vitro experiments: (i) activation of the blood coagulation system, which proceeds through a cascade mechanism, incorporates biochemical amplification; (ii) the inhibition of activated Factor IX by antithrombin III in the presence of heparin is an important reaction in the prevention of thrombosis; (iii) less heparin is required to inhibit thrombosis prior to thrombin generation than afterward; (iv) an increase in the reactivity of antithrombin III reflects a decreased tendency to thrombosis while a decrease in this reactivity reflects an increased tendency to thrombosis.
D000818:Animals; D000991:Antithrombins / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005164:Factor IX / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005170:Factor X / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006493:Heparin / Q000494:pharmacology*; D011817:Rabbits; D012910:Snake Venoms / Q000494:pharmacology*; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013927:Thrombosis / Q000097:blood
D000991:Antithrombins; D012910:Snake Venoms; D005164:Factor IX; D005170:Factor X; D006493:Heparin; D013917:Thrombin
J Appl Physiol. 1959 Nov;14:943-6
13844118
Am J Physiol. 1956 Mar;184(3):627-39
13302473
J Am Med Assoc. 1950 Feb 25;142(8):527-34
15403258
Thromb Diath Haemorrh. 1965 Jun 15;13:516-30
14347873
Science. 1964 Sep 18;145(3638):1310-2
14173416
Nature. 1964 May 2;202:498-9
14167839
Am J Med. 1962 Nov;33:648-66
14000083
Nature. 1962 Mar 24;193:1188
14455845
Circ Res. 1955 Jul;3(4):397-402
14390722
JAMA. 1976 Nov 8;236(19):2179-82
989807
Biochemistry. 1976 Nov 2;15(22):4901-6
990251
J Biol Chem. 1971 Jun 10;246(11):3694-702
4102936
Ann Intern Med. 1974 Dec;81(6):766-70
4433081
N Engl J Med. 1974 Feb 14;290(7):403-4
4810120
N Engl J Med. 1973 Sep 13;289(11):592
4723113
N Engl J Med. 1973 Jul 19;289(3):160
4711352
Folia Med Neerl. 1967;10(4):112-25
6073947
Scand J Haematol. 1976 Jul;17(1):29-35
959771
J Biol Chem. 1974 Jul 25;249(14):4335-8
4276455
Nature. 1973 Dec 7;246(5432):355-7
4586320
N Engl J Med. 1975 Jan 16;292(3):146-51
127943
Blood. 1974 Feb;43(2):219-31
4810073
Circulation. 1974 Apr;49(4):603-5
4817700
Biochemistry. 1976 Jan 27;15(2):373-7
1247523
Thromb Res. 1976 Feb;8(2):195-204
1251350
Thromb Res. 1976 Feb;8(2):167-71
1251348
Thromb Diath Haemorrh. 1975 Jun 30;33(3):617-31
1154317
Thromb Diath Haemorrh. 1975 Jun 30;33(3):564-72
1154312
Biochim Biophys Acta. 1971 Nov 12;252(2):255-61
5167338
Br J Haematol. 1970 Sep;19(3):283-305
5529547
Biochim Biophys Acta. 1970 Feb 24;201(2):387-90
5418732
Fed Proc. 1969 Jan-Feb;28(1):160-1
5763994
Br Med J. 1968 Apr 27;2(5599):199-205
5653025
J Biol Chem. 1968 Jan 10;243(1):112-7
5635939
Scand J Clin Lab Invest. 1968;21(1):89-91
5637480